Headache News and Research

Latest Headache News and Research

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine.

17 Jun 2014

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

A new study presented for the first time today at the European League Against Rheumatism Annual Congress (EULAR 2014), shows that cranial ultrasound has a greater sensitivity than temporal artery biopsy,* and a comparable specificity in the diagnosis of Giant Cell Arteritis (GCA).

13 Jun 2014

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.

12 Jun 2014

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

12 Jun 2014

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel).

11 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

1% of adults experience headaches associated with sexual activity, shows report

About 1 percent of adults report they have experienced headaches associated with sexual activity, and that such headaches can be severe.

10 Jun 2014

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

In a multi-center, randomized, trial across Europe, electroCore's non-invasive vagus nerve stimulation (nVNS) therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.

10 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

A simple blood test can detect if a person is one of the two billion people worldwide infected with hepatitis B. And now the U.S. Preventive Services Task Force recommends that all teens and adults who are high risk for hepatitis B get screened for the infection.

6 Jun 2014

New report focuses attention on wait times at El Paso VA facility

The document, which was commissioned by Rep. Beto O'Rourke, D-Texas, found wait times as long as 71 days for veterans who sought mental health treatment at the facility. This finding was very different from official statistics.

6 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

HHS probes data discrepancies for 2 million enrollees

Administration officials said that in most cases, those discrepancies will not affect consumers' coverage or the level of subsidies they received. Individuals are being asked to submit additional documentation to ensure they're getting the correct tax credits.

6 Jun 2014

Terminix warns about two serious mosquito-borne diseases in Florida

Terminix, the leading provider of termite and pest control services in the United States, today warned of two serious mosquito-borne diseases which are being reported in Florida. The Florida Department of Health this week issued a report confirming 18 cases of chikungunya virus and 24 cases of dengue fever.

6 Jun 2014

First Edition: June 5, 2014

Today's headlines include the latest developments regarding congressional action on the veterans' health care scandal as well as reports about the latest Medicaid enrollment figures in the context of the health law.

5 Jun 2014

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine.

5 Jun 2014

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV).

4 Jun 2014

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities.

3 Jun 2014

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

3 Jun 2014

Headache News and Research

Latest Headache News and Research

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Auxilium and Prasco introduce authorized generic version of Testim

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

1% of adults experience headaches associated with sexual activity, shows report

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

New report focuses attention on wait times at El Paso VA facility

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

HHS probes data discrepancies for 2 million enrollees

Terminix warns about two serious mosquito-borne diseases in Florida

First Edition: June 5, 2014

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in